Original Articles: Prostate Cancer: Detailed Preliminary Analysis of Iodine-125 Implantation for Localized Prostate Cancer Using Percutaneous Approach

Kaye, Keith W.; Olson, Douglas J. H.; Payne, Junaidi

doi:10.1016/s0022-5347(01)67626-2

Cited by 103 publications

(49 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Snyder et al and Kaye et al reported no episodes of chronic radiation proctitis after the third year postimplantation. 42, 43 Gelblum and Potters reported a peak incidence (9.5%) of rectal complications at 8 months after implantation, and no patients had rectal symptoms at 42 months. 16 Snyder et al observed an increased incidence of radiation proctitis the first year after implantation; 14% of their patients developed symptoms in the first year, and 72% had symptoms in the second year, whereas the majority reported symptom resolution after the third year.…”

Section: Incidence Of Late Rectal Complicationsmentioning

confidence: 96%

Late rectal complications after prostate brachytherapy for localized prostate cancer

Phan¹,

Swanson²,

Levy³

et al. 2009

Cancer

View full text Add to dashboard Cite

This review of the literature on late rectal complications after prostate brachytherapy indicated that it is a highly effective treatment modality for patients with clinically localized prostate cancer but can cause chronic radiation proctitis. The most common manifestation of chronic radiation proctitis was anterior rectal wall bleeding, which often occurred within the first 2 years after brachytherapy. It is interesting to note that the rates of late rectal morbidity appear to have declined over time, which may reflect improvements in implantation techniques and imaging. Rectal biopsy as part of the workup to evaluate rectal bleeding can lead to rectal fistula and the need for colostomy, a rare but major complication. The authors recommend 1) screening colonoscopy before brachytherapy for patients who have not had a screening colonoscopy within the preceding 3 years to rule out colorectal malignancies and, thus, facilitate conservative management should rectal bleeding occur; 2) lifestyle modifications during treatment to limit exposure of the rectum to radiation; and 3) conservative management for rectal bleeding that occurs within 2 years after brachytherapy. Prostate cancer is the leading cause of cancer in men and accounts for approximately 33% of cancer deaths among men in the US.1,2 Management options for organ-confined, low-to intermediate-risk prostate cancer include watchful waiting, radical prostatectomy, external-beam radiation therapy, and prostate brachytherapy with permanent interstitial implants. Recent improvements in radioactive seed implantation techniques have established prostate brachytherapy as a highly effective treatment modality for localized prostate cancer, with long-term local and biochemical control similar to outcomes observed after radical prostatectomy and external-beam radiation therapy. 3,4 Because prostate cancer is diagnosed

show abstract

Section: Incidence Of Late Rectal Complicationsmentioning

confidence: 96%

Late rectal complications after prostate brachytherapy for localized prostate cancer

Phan¹,

Swanson²,

Levy³

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…Review of the contemporary transperineal experience using template and image guidance is still ongoing. [22][23][24][25][26][27][28][29][30][31][32][33] While some early studies 22,31 indicate significant proportions of tumor-positive biopsies postimplantation and/or distant metastases, most of the large published series [24][25][26]29 have shown PSA-based control rates comparable to prostatectomy or external beam radiation. A notable study by Vijverberg et al 33 examined biopsy findings postimplantation and the quality of the implant in terms of the minimum dose delivered to the prostate.…”

Section: Introductionmentioning

confidence: 99%

Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64

et al. 1999

View full text Add to dashboard Cite

There is now considerable evidence to suggest that technical innovations, 3D image-based planning, template guidance, computerized dosimetry analysis and improved quality assurance practice have converged in synergy in modern prostate brachytherapy, which promise to lead to increased tumor control and decreased toxicity. A substantial part of the medical physicist's contribution to this multi-disciplinary modality has a direct impact on the factors that may singly or jointly determine the treatment outcome. It is therefore of paramount importance for the medical physics community to establish a uniform standard of practice for prostate brachytherapy physics, so that the therapeutic potential of the modality can be maximally and consistently realized in the wider healthcare community. A recent survey in the U.S. for prostate brachytherapy revealed alarming variance in the pattern of practice in physics and dosimetry, particularly in regard to dose calculation, seed assay and time/method of postimplant imaging. Because of the large number of start-up programs at this time, it is essential that the roles and responsibilities of the medical physicist be clearly defined, consistent with the pivotal nature of the clinical physics component in assuring the ultimate success of prostate brachytherapy. It was against this background that the Radiation Therapy Committee of the American Association of Physicists in Medicine formed Task Group No. 64, which was charged ͑1͒ to review the current techniques in prostate seed implant brachytherapy, ͑2͒ to summarize the present knowledge in treatment planning, dose specification and reporting, ͑3͒ to recommend practical guidelines for the clinical medical physicist, and ͑4͒ to identify issues for future investigation.

show abstract

“…18 This low rate of incontinence was attributed to distributing the radioactive seeds at some distance from the urethra. Early series 7,8 reported maintenance of potency in 81% and 75% of previously potent patients after 2±3 y respectively. Blasko et al 17 reported that 85% of under 70s and 50% of over 70s remained potent 3 y after prostate brachytherapy.…”

Section: Complicationsmentioning

confidence: 99%

Prostate brachytherapy

Ash

Bottomley

Carey

1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Original Articles: Prostate Cancer: Detailed Preliminary Analysis of Iodine-125 Implantation for Localized Prostate Cancer Using Percutaneous Approach

Cited by 103 publications

References 18 publications

Late rectal complications after prostate brachytherapy for localized prostate cancer

Late rectal complications after prostate brachytherapy for localized prostate cancer

Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64

Prostate brachytherapy

Contact Info

Product

Resources

About